Teens and antidepressants: did warnings go too far?
Teens and Antidepressants: Did Warnings Go Too Far?
Did an effort to reduce teen suicides backfire?
By Tony Dokoupil Newsweek
July 16, 2007 issue - Seventeen-year-old Michael didn't want to end up crazed and suicidal like the Columbine killers.
The Massachusetts teen had read that Eric Harris and Dylan Klebold were taking antidepressants when they rampaged
murderously through their Colorado high school in 1999, and he didn't want to snap as they had. "He'd say it was like
there was an evil guy on his left shoulder and a good guy on his right, but the evil guy just kept winning," Michael's mother, Lorraine, recalls. Despite his pain, Michael feared that antidepressants would "put him over the edge."
Lorraine wasn't so sure. After consulting a specialist, she persuaded Michael in January to try Prozac, one of a family
of drugs known as selective serotonin reuptake inhibitors, or SSRIs. By spring, the "good guy" was winning: Michael
Lorraine can't know for certain whether Prozac saved Michael's life, although she's convinced it did. These days,
however, fewer parents or doctors are following her lead. According to a new study in The Journal of American
Psychiatry, the number of SSRI prescriptions for pediatric depression (ages 5 to 18) tumbled more than 50 percent
between 2003 and 2005. In a troubling parallel development, the number of teen suicides jumped a record 18 percent between 2003 and 2004, the most recent year for which data exist.
Are the two trends connected? Many experts say yes. "All the data point in one direction: antidepressants save lives and untreated depression kills people," says Dr. Kelly Posner, a Columbia University child psychiatrist. She and others
cite an unwitting instigator: the Food and Drug Administration—which may have scared parents and doctors away
from SSRIs in 2003 when it issued a health-advisory warning of a potential link between the popular drugs and teen
suicide. The agency, assisted at the time by Posner, followed up in 2004 with a "black box" warning of an "increased
risk of suicidal thinking and behavior among children and adolescents." Now, amid fears that it's done more harm
than good, there are calls for the FDA to modify and even repeal its black box. "I think the FDA has made a very serious mistake. It should lift its black-box warning because all it's doing is killing kids," says Dr. Robert Gibbons, of
the University of Illinois's Center for Health Statistics. (Gibbons was a dissenting member of the FDA advisory
committee that voted for the black box.) Others agree, including Dr. John Mann, a suicide expert at Columbia
University, who fought the warning on the ground that it would have a chilling effect on treatment. "Short of
rescinding, the FDA should shift its balance to reflect new wisdom about the beneficial effects of antidepressants," he
says. Drugmakers continue to support the FDA but also suspect its actions have had a dangerous impact.
These new attacks are in contrast to the praise the FDA elicited with its move for more-stringent labeling, which
followed searing public testimony from parents whose children killed themselves while taking SSRIs. The pendulum
has since swung back. "If I had known how much the label would rattle parents, I wouldn't have voted for it," says Gail Griffith, who was the patient representative on the panel. Today, few doubt the FDA's good intentions, or its
conclusion that teens taking the drugs should be closely monitored. Psychiatrists have long thought that treatment
can put people at a temporary risk of suicide, but untreated depression is considered the far more lethal course. "You
may induce two suicides by treatment, but by stopping treatment you're going to lose dozens to hundreds of kids.
You're losing more than you're saving. That's the calculus," says Dr. Robert Valuck, of the University of Colorado
Heath Sciences Center, coauthor of the new paper. (The research, partly funded by Prozac maker Eli Lilly, passed a peer review for bias.)
The FDA has already taken steps to modify the box in reaction to reports that its message was being misunderstood. "Our goal was to inform people of a risk, not halt treatment," says Dr. Thomas Laughren, head of psychiatry products,
the division responsible for the warning. "But it's still only one year of data," he cautions. In May, his office mandated
revisions "to reflect the apparent beneficial effect of antidepressants" and remind people that mood disorders are "the
The next test for the FDA will come this December, when the CDC releases suicide figures for 2005. "If the rates are
up again, it's likely we'll go back to the board of advisers," says Laughren. The agency has repealed only one black
box in its history, on the acid-reflux medication Prilosec, pulled in 2003. "But I wouldn't rule it out," Laughren adds.
"The evidence is very compelling."
PROCES VERBAL DE LA REUNION DU CA/ATDM 34 DU 26 mars 2009 PARTICIPANTS (13): Georges BARTOLI, Jacques BOUTHIER, Paul CHASSAGNEUX, Roger DEON, José DESMERGERS, Jean Yvon FEVRIER, Roger FIORIO, Louis LARMANDE, Raoul LARTIGUE, Yvan NICAISE, Patrick PACAUD, Vincent RABOT, Roger RAYBOIS. LIEU : Bridge Club Occitan à Montpellier. DEJEUNER : sur place - 12 participants ASSEMBLEE G
QUICK REFERENCE: SWINE FLU The United States declared a public health emergency in response to the recent reports of swine flu. UnitedHealthcare wants to help you understand some important facts about swine flu is so you may take appropriate actions to help protect yourself and your family. We also recommend the CDC website or contacting a medical professional for more information. The viru